| [ Summary ] |
Compared with the general population, dialysis patients are at increased risk of bone fractures. Denosumab, a fully human monoclonal antibody with high affinity and specificity for RANK ligand, reduces osteoclast activity and bone resorption. It is used to treat osteoporosis in the general population, and could be efficacious in patients with decreased kidney function. However, when using denosumab for patients with CKD, it is necessary to pay sufficient attention to severe hypocalcemia and a compensatory iPTH increase. Supplying active vitamin D and carefully monitoring serum calcium during denosumab treatment should be considered. |